1. Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria
- Author
-
Adeyemi A Okunowo, Adaiah P. Soibi-Harry, Olayemi Olubunmi Dawodu, Omolola Salako, Ephraim O Ohazurike, Rose I Anorlu, Kehinde S Okunade, Adebola A Adejimi, Benedetto Osunwusi, Aloy Okechukwu Ugwu, Jonathan S. Berek, and Muisi A Adenekan
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,MEDLINE ,Nigeria ,Kaplan-Meier Estimate ,Carcinoma, Ovarian Epithelial ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Carcinoma ,Overall survival ,Humans ,Medicine ,Epithelial ovarian cancer ,In patient ,030212 general & internal medicine ,Retrospective Studies ,Ovarian Neoplasms ,business.industry ,Retrospective cohort study ,ORIGINAL REPORTS ,Middle Aged ,medicine.disease ,030220 oncology & carcinogenesis ,Female ,Primary treatment ,business ,Gynecological Cancer - Abstract
PURPOSE This study was designed to investigate the clinicopathologic predictors of progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (EOC) following primary treatment in Lagos, Nigeria. MATERIALS AND METHODS Using data from a retrospective cohort of 126 patients who received treatment for EOC between 2010 and 2018, we identified 83 patients with a complete clinical record for subsequent data analysis. Patients' demographics and updated 2-year follow-up status were abstracted from medical records. Kaplan-Meier survival curves were compared using the log-rank test, and Cox proportional hazard models were used for multivariate analysis to identify independent predictors of survivals following treatment in EOC patients. RESULTS The median PFS and OS were 12 and 24 months, respectively. After adjusting for covariates in the multivariate analysis, younger age ≤ 55 years (hazard ratio [HR] = 0.40; 95% CI, 0.22 to 0.74; P = .01) and International Federation of Gynecology and Obstetrics (FIGO) stage I/II (HR = 0.02; 95% CI, 0.01 to 0.08; P = .01) were independent predictors of improved PFS, whereas being premenopausal (HR = 2.34; 95% CI, 1.16 to 4.75; P = .02) was an independent predictor of reduced OS after 2-year follow-up. CONCLUSION PFS could be predicted by the age and FIGO stage of the disease, whereas menopausal status was predictive of OS in patients with EOC. This knowledge should form the basis for counseling patients with ovarian cancer during their primary treatment and lend support to the importance of aggressive follow-up and monitoring for the older, premenopausal patients and those with an advanced stage of epithelial ovarian cancer. However, robust longitudinal research should be carried out to provide additional reliable insight to this information.
- Published
- 2021